Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
The phase 1/2 trial (NCT03277729) is evaluating the efficacy and safety of cellular immunotherapy using autologous T cells that express a CD20-specific CAR in patients with relapsed/refractory NHL and CLL.
When evaluating the follicular lymphoma cohort (n = 18), the overall response (ORR) rate was 94%, and of the 18 evaluable patients, 14 (78%) had a complete remission (CR) as their best response, Shadman says. Across all patients, the response rate was 96%, with a 72% CR rate, Shadman explains. Additionally, a subset of the population has maintained their remission for more than 2 years, and 5 patients have surpassed 1 year of being in remission. These long-term responses are consistent with the T-cell expansion that has been seen with other CAR T-cell therapies, Shadman adds.
In terms of safety, a favorable safety profile was seen with no grade 3/4 cytokine release syndrome and no grade 3/4 neurotoxicity in the overall patient population, Shadman says. Overall, safety is very important when picking a treatment, especially for those who are otherwise unfit to receive CD19-directed CAR T-cell therapy, Shadman concludes.